Insights

The average generic drug program takes 3 to 4 years from target identification to FDA approval. For most companies, that […]

Strategic Patent Barriers and Market Exclusivity in the Pharmaceutical Industry Pharmaceutical companies use patent portfolios to prevent generic and biosimilar

How AI, blockchain, multi-sourcing, and smarter policy can cut costs, eliminate fragility, and keep patients supplied Generic drugs fill 89%

A technical deep dive for pharma IP teams, R&D leads, and institutional investors Master Key Takeaways A drug’s market monopoly

For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need more than headline growth figures. Executive Summary

A patent does not generate revenue. A masterfully executed commercial strategy does. This guide breaks down exactly how pharmaceutical companies,

1. The Structural Economics of Generic Affordability 1.1 The Arithmetic Behind the 80-85% Discount Generic drugs fill roughly 90% of

The economic lifeblood of a pharmaceutical company is the period of market exclusivity granted by its patent portfolio. For most

The global biologics market crossed $400 billion in annual revenue in 2023 and is tracking toward $600 billion by 2026